New approaches to high-throughput single cell multiomic CRISPR screening
For decades, the complexity and heterogeneity of cancer cells have been a relentless challenge, obscuring the most effective drug targets within a fog of bulk data. In this blog article we highlight a pivotal moment: the advent of large-scale, multiomic single-cell CRISPR screening. This technology is a game-changer, acting as a high-powered lens that finally links precise genetic challenges (CRISPR-gRNA) directly to the resulting cellular response (multiomic phenotype) in thousands of cells. The presented case studies show this is not theoretical—it’s already revealing actionable targets. For drug developers, this provides the definitive evidence and throughput necessary to transition from educated guesses to high-confidence target validation for the next generation of cancer therapeutics.
3 reasons — and key takeaways — that make this blog worth your time
- Case Study (AT/RT Cancer): Explore a real-world example where MultiPerturb-seq uncovered ZNHIT1 as a differentiation therapy target in a rare pediatric brain tumor.
- Case Study (T-ALL): See how the methodology successfully defined the function of recurrently mutated genes in T-cell leukemia, identifying key tumor suppressors and critical signaling pathways (STAT/NOTCH).
- Technical Note: Learn why increasing scale with the GEM-X Flex workflow is critical for building large-scale Perturbation Cell Atlases, providing the raw, high-content data needed to train AI models for next-generation drug discovery.
